Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
Hagop M Kantarjian1, Daniel J DeAngelo1, Matthias Stelljes1
1From the University of Texas MD Anderson Cancer Center, Houston (H.M.K.); the Dana-Farber Cancer Institute, Boston (D.J.D.), and Pfizer, Cambridge (E.V.) - both in Massachusetts; Universitätsklinikum Münster, Münster (M.S.), and Goethe University, Frankfurt (N.G.) - both in Germany; Institute Seràgnoli, DIMES (Department of Experimental, Diagnostic and Specialty Medicine), University of Bologna, Bologna, Italy (G.M.); Stanford Cancer Institute, Stanford (M.L.), and the University of California, Irvine Medical Center, Orange (S.O.) - both in California; the University of Chicago, Chicago (W.S.); Pfizer, Pearl River, NY (K.W.); Pfizer, Groton, CT (T.W., M.L.P., B.S.); and Cleveland Clinic, Cleveland (A.S.A.).
Inotuzumab ozogamicin significantly improved complete remission rates and survival for adults with relapsed acute lymphoblastic leukemia compared to standard chemotherapy. However, liver-related adverse events, including veno-occlusive liver disease, were more frequent.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Adults with relapsed acute lymphoblastic leukemia (ALL) face a poor prognosis.
- Standard therapies offer limited success in managing relapsed or refractory ALL.
Purpose of the Study:
- To evaluate if inotuzumab ozogamicin improves outcomes in patients with relapsed or refractory ALL compared to standard therapy.
- To assess complete remission rates and overall survival in this patient population.
Main Methods:
- A Phase 3 randomized trial comparing inotuzumab ozogamicin to standard intensive chemotherapy.
- Adult patients with relapsed or refractory ALL were assigned to either treatment arm.
- Primary endpoints included complete remission and overall survival.
Main Results:
- Inotuzumab ozogamicin demonstrated a significantly higher complete remission rate (80.7% vs. 29.4%) compared to standard therapy.
- Patients receiving inotuzumab ozogamicin achieved longer remission duration and improved progression-free survival.
- Median overall survival was also longer in the inotuzumab ozogamicin group (7.7 months vs. 6.7 months).
Conclusions:
- Inotuzumab ozogamicin offers a superior complete remission rate and improved survival outcomes for relapsed or refractory ALL.
- A significant proportion of patients on inotuzumab ozogamicin achieved minimal residual disease negativity.
- Veno-occlusive liver disease emerged as a notable adverse event associated with inotuzumab ozogamicin treatment.
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...